...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Southern Med Review >Eliciting the public preferences for pharmaceutical subsidy in Iran: a discrete choice experiment study
【24h】

Eliciting the public preferences for pharmaceutical subsidy in Iran: a discrete choice experiment study

机译：引诱伊朗药物补贴的公共偏好：一个离散的选择实验研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Deciding on pharmaceutical subsidy is regarded as a challenging issue for healthcare policymakers in Iran in most times. Public preferences, rarely attended in Iran, could be invaluable for including a particular drug in the list of subsidized medications. The current study aims to elicit the public preferences to develop an evidence-based decision-making framework for entering a drug into the list of subsidies in Iran. Discrete Choice Experiment (DCE) was employed to elicit the public preferences. Around 34 attributes were identified based on the systematic review and interview with 51 experts. By holding an expert panel, 7 attributes were finalized, namely: the survival after treatment, quality of life after treatment (QoL), alternative treatment, age group of the target population, cost burden for the government, disease severity, and drug manufacturer country. Next, 1224 households were selected for the survey in the city of Tehran, using random cluster sampling. Data were analyzed using conditional logit model. The survival after treatment (β?=?1.245; SE?=?0.053) and disease severity (β?=??0.143; SE?=?0.043) had the highest and lowest priority, respectively, in the preferences for allocating subsidy to a drug. In developed region, unlike the other two regions, the level of domestic drug production (β?=??0.302; SE?=?0.073) was inversely associated with preferences toward allocating subsidy to a drug. In contrast to other districts, those living in district number one (β?=?2.053; SE?=?0.138) gave the highest value to promoting the QoL after treatment. It is suggested that policymakers pay more attention to attributes such as effectiveness and alternative treatment when developing an evidence-based framework for entering a drug into the list of subsidies. This study highlighted the public belief in the government’s subsidy for medicines, provided that, this results in an increased survival and QoL.
机译：决定在大多数时候被视为伊朗医疗保健政策制定者的挑战性问题。公众偏好，很少参加伊朗，可能是在补贴药物清单中包括特定药物的宝贵。目前的研究旨在引出公众偏好，制定一个基于证据的决策框架，以进入伊朗补贴名单。采用离散选择实验（DCE）引出公众偏好。根据系统审查和采访51名专家，确定了大约34个属性。通过持有专家面板，7个属性最终确定：治疗后的存活，治疗后的生活质量（QOL），替代治疗，目标人口的年龄组，政府的成本负担，疾病严重程度和药品厂商国家。接下来，使用随机群集采样，为德黑兰市进行调查选择了1224户家庭。使用条件Logit模型进行分析数据。治疗后的存活率（β？=？1.245; SE？= 0.053）和疾病严重程度（β？= ?? 0.143; SE？= 0.043）分别在分配补贴的偏好方面具有最高和最低的优先级一种药物。在发达地区，与其他两个地区不同，国内药物生产水平（β？= 0.302; SE？= 0.073）与分配对药物的补贴的偏好相反。与其他地区相比，那些生活在地区的人（β？=？2.053; SE？=？0.138）给出了治疗后促进QoL的最高值。建议在制定基于证据的框架进入补贴名单时，政策制定者更加关注有效性和替代治疗等效果和替代治疗。本研究强调了政府对药物补贴的公众信念，规定这导致生存和QOL增加。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号